MET and non-small cell lung carcinoma: Consequently, the inhibition of MET alone does not effectively suppress the Wnt/β‐catenin signaling pathway in this case, thereby providing a reasonable explanation as to why the combined treatment of EGFR‐TKIs and MET‐TKIs is unsatisfactory against acquired resistance attributed to MET amplification in patients with EGFR‐mutant NSCLC.